CIRM Funded Clinical Trials
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML
Colleen Delaney
Disease Area:
Leukemia, Acute Myeloid (AML)
Investigator:
Institution:
CIRM Grant:
CLIN2-09574 (Closed)
Award Value:
$4,310,000
Trial Sponsor:
Trial Stage:
Phase 2
Trial Status:
Closed
Targeted Enrollment:
146
ClinicalTrials.gov ID:
Details:
Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.
Design:
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.
Goal:
Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.
